| Literature DB >> 18830237 |
Christina M Gremel1, Christopher L Cunningham.
Abstract
Although progress has been made identifying neural mechanisms underlying ethanol's primary reinforcing effects, few studies have examined the mechanisms mediating ethanol-induced conditioned effects. A recent lesion study suggests that expression of ethanol-conditioned behaviors depends upon an intact amygdala and nucleus accumbens core. However, specific mechanisms within these nuclei are unknown. In the present experiments, we used site-specific microinfusions of dopamine and NMDA receptor antagonists to examine the roles of accumbens and amygdala in the expression of ethanol conditioned place preference (CPP) in mice. In experiments 1 and 2, a D1/D2/D3 receptor antagonist (flupenthixol) was infused into accumbens or amygdala before testing, whereas experiment 3 used pretest infusions of an NMDA antagonist (AP-5) to examine the role of intra-accumbens NMDA receptors. Dopamine antagonism of accumbens was without effect, but intra-amygdala infusions of flupenthixol blocked CPP expression. Moreover, this effect was dependent upon dopamine antagonism within the basolateral nucleus but not the central nucleus of the amygdala. Antagonism of NMDA receptors in accumbens also blocked CPP expression. The present findings suggest that expression of the ethanol-conditioned response depends upon amygdala dopamine and accumbens NMDA receptors. These are the first studies in any species to show a role for amygdala dopamine receptors and the first studies in mice to implicate accumbens NMDA receptors in ethanol-induced conditioned effects.Entities:
Mesh:
Substances:
Year: 2008 PMID: 18830237 PMCID: PMC2678896 DOI: 10.1038/npp.2008.179
Source DB: PubMed Journal: Neuropsychopharmacology ISSN: 0893-133X Impact factor: 7.853
Subject removal
| | Initial | Final | Surgery & Recovery | Procedural error | Histology error | Miss | Infection |
|---|---|---|---|---|---|---|---|
| Experiment 1 | 216 | 109 | 6 | 3 | 8 | 39 | 51 |
| Experiment 2 | 190 | 74 | 36 | 4 | 7 | 50 | 19 |
| Experiment 3 | 94 | 63 | - | 4 | 2 | 7 | 18 |
Figure 1Representative diagram and photomicrograhs of Acb and Amy injector placements. Representative injector inclusion area criteria are shown for Acb (column A) and Amy (Column B). In column C, photomicrographs of representative injector tracks into BLA (upper left panel), CE (lower left panel), BM (upper right panel), and Acb (lower right panel). Photomicrographs are oriented with the medial portion of the brain on the left, and the lateral portion of the right in each photo, and nearby anatomical landmarks are identified. Numbers indicate the distance from bregma in millimeters of the section (Paxinos & Franklin, 2001).
Figure 2Intra-Acb microinfusions of flupenthixol did not affect expression of ethanol CPP. Mean sec per min (+SEM) spent on the grid floor during the 30-min test session. Subjects in the Grid+ conditioning subgroups (solid bars) received ethanol paired with the grid floor on CS+ trials, and saline paired with the hole floor. These contingencies were reversed in the Grid-conditioning subgroup subjects (grey bars). N's for Grid+ and Grid- conditioning subgroups are: aCSF n = 28 and 18; 1 μg/side n = 5 and 4; 10 μg/side n = 13 and 12, and 20 μg/side n = 15 and 14. # = Main effect of conditioning between Conditioning Subgroups, p < 0.001.
Figure 3Flupenthixol infused into the Amy disrupts expression of ethanol CPP. Mean sec per min (+SEM) spent on the grid floor during the 30-min test session. (A) Effects of intra-Amy (BLA and CE) infusions of flupenthixol on expression of ethanol CPP. Grid+ and Grid-conditioning subgroup N's are: aCSF n = 13 and 18; 10 μg/side n = 4 and 4; and 20 μg/side n = 18 and 17. (B) Flupenthixol infusions into the BLA, but not CE disrupt expression of ethanol CPP. Test data for aCSF and 20 μg/side dose groups grouped by injector site within the Amy, combined with subjects (aCSF and 20 μg/side) with injector placements within the BM. Grid+ and Grid- Conditioning subgroup N's are: aCSF n = 15 and 22; BLA n = 10 and 4; CE n = 4 and 6; Both n = 4 and 7, and BM n = 3 and 3. Difference between conditioning subgroups Grid+ and Grid-: *** = Bonferroni corrected ps < 0.001.
Figure 4Infusions of AP-5 into the AcbC disrupted expression of ethanol CPP. Mean sec per min (+SEM) spent on the grid floor during the 30 min of the test session. Grid+ and Grid-conditioning subgroups N's are respectively: aCSF n = 10 and 13; 0.5 μg/side n = 9 and 12; 1.0 μg/side n = 11 and 8. Difference between conditioning subgroups Grid+ and Grid-: *** = Bonferroni corrected ps < 0.001.
Locomotor Activity
| | Dose μg/side | CS+ trials counts/min ± SEM | CS- trials counts/min ± SEM | Mean test activity counts/min ± SEM | |
|---|---|---|---|---|---|
| Experiment 1 | | | |||
| aCSF | 46 | 196 ± 5 | 76 ± 2 | 47 ± 2 | |
| 1 | 9 | 178 ± 5 | 63 ± 4 | 34 ± 3 | |
| 10 | 25 | 210 ± 6 | 79 ± 3 | 36 ± 2 | |
| 20 | 29 | 203 ± 7 | 80 ± 5 | 30 ± 2 | |
| Dose Group: F(3,105) = 3.2 | Dose Group: F(3,105): 12.8 | ||||
| | Trial Type: F(1,105) = 966.9 | | |||
| Experiment 2 | | ||||
| aCSF | 31 | 177 ± 4 | 69 ± 2 | 39 ± 2 | |
| 10 | 8 | 159 ± 12 | 66 ± 6 | 33 ± 2 | |
| 20 | 35 | 179 ± 6 | 68 ± 3 | 27 ± 2 | |
| | Trial Type: F(1,71) = 527.2 | Dose Group: F(2,71) = 11.7 | |||
| Experiment 3 | | ||||
| aCSF | 23 | 183 ± 8 | 69 ± 2 | 41 ± 2 | |
| .5 | 21 | 189 ± 8 | 74 ± 3 | 51 ± 3 | |
| 1.0 | 19 | 191 ± 11 | 72 ± 4 | 74 ± 6 | |
| Trial Type: F(1,60) = 870.6 | Dose Group: F(2,60) = 17.8 | ||||
p < 0.05
p < 0.001 (p-values for all group comparisons are Bonferroni-corrected).
= difference from aCSF Group, p < 0.001
= difference from aCSF Group, p < 0.01
= difference from aCSF Group, p < 0.05
= 1.0 μg/side Group significantly different from 0.5 μg/side Group, p < 0.05
= 1 μg/side Group activity means significantly different from 10 μg/side Group mean, p < 0.05.